Back to top
more

Bolt Biotherapeutics (BOLT)

(Delayed Data from NSDQ)

$5.62 USD

5.62
9,797

+0.09 (1.63%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

by Zacks Equity Research

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

Zacks Equity Research

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

by Zacks Equity Research

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Zacks Equity Research

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

by Zacks Equity Research

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

Zacks Equity Research

Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints

by Zacks Equity Research

Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.

Zacks Equity Research

Bausch (BHC) Suspends IPO Plans for Solta Medical

by Zacks Equity Research

Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

Zacks Equity Research

Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug

by Zacks Equity Research

Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.

Zacks Equity Research

Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery

by Zacks Equity Research

Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery are part of screen of the week article.

Zacks Equity Research

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

by Zacks Equity Research

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

Kinjel Shah headshot

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Zacks Equity Research

BOLT Enters Into a Collaboration Agreement With Bristol Myers

by Zacks Equity Research

BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.